The past, present, and future of immunotherapy for endometrial adenocarcinoma

• Published in: Medical oncology (Northwood, London, England) Vol. 40; no. 7; p. 186
• Main Authors: Jones, Anna C., Brown, Karah H., Guan, Tianyun, Smith, Luke A., Formslag, Cole R., Farjado, Emerson D., Bai, Qian, Luechtefeld, Harrison D., Wakefield, Mark R., Dong, Lijun, Fang, Yujiang
• Format: Journal Article
• Language: English
• Published: New York Springer US 23-05-2023; Springer Nature B.V
• Subjects: Adenocarcinoma; Antibodies; Cancer therapies; Cells; Cytotoxicity; Endometrial cancer; Female; Hematology; Humans; Hysterectomy; Immune system; Immunotherapy; Immunotherapy, Adoptive; Internal Medicine; Kinases; Ligands; Medical prognosis; Medicine; Medicine & Public Health; Metabolism; Metastasis; Oncology; Pathology; Review Article; Surgery; Tumors; Vaccination; Vaccines; Yeast; Endometrial cancer; Immunotherapy
• ISSN: 1559-131X; 1357-0560; 1559-131X
• DOI: 10.1007/s12032-023-02040-7

Incidences of endometrial adenocarcinoma are increasing in the USA with poor prognosis for patients with advanced disease. The current treatment standard is surgery including total hysterectomy and bilateral oophorectomy with surgical staging and adjunct treatment, such as chemotherapy or radiation. However, these methods do not present as an effective treatment option for poorly differentiated advanced cancers. Advancements in immunotherapy now offer a new approach for various types of cancer and specifically show promise in the treatment of endometrial adenocarcinoma. This review summarizes immunotherapeutic treatment options relevant to endometrial adenocarcinoma, such as immune checkpoint blockades, bispecific T-cell engager antibodies, vaccinations, and adoptive cell transfer. This study could be helpful for clinicians to identify treatment options more suitable for women with late-stage endometrial adenocarcinoma.